Abstract: Polypeptides comprising variant vascular endothelial growth factor sequences are provided. The polypeptides are useful in cancer imaging, cancer diagnosis, monitoring and treatment as well as treatment of diseases characterized by excessive neovascularization.

Abstract: This document provides methods and materials related to natriuretic polypeptides and the use of natriuretic polypeptides to treat cardiovascular and/or renal conditions. For example, chimeric polypeptides having at least one amino acid segment (e.g., N-terminus tail, ring structure, C-terminus tail, or a combination thereof) of a natriuretic peptide (e.g., ANP, BNP, CNP, URO, or DNP) and an amino acid segment of an angiotensin polypeptide (e.g., Ang-(1-7)) are provided.

Abstract: The present invention relates to methods for the purification of polypeptides using counter current chromatography. In particular the present invention relates to the use of counter current chromatography for the purification of recombinant GLP-1.

Abstract: The invention provides compositions and methods for treating a disease or disorder associated with vascular endothelial growth factor (VEGF). Specifically, the invention relates to an oligomerized VEGF binding domain to provide VEGF antagonism, and thereby treat diseases associated thereof.

Abstract: Disclosed is a method for producing proteins having factor VIII procoagulant activity in serum-free medium by in vitro culturing of mammalian cells, wherein the serum-free medium contains an inhibitor against the protease released from cultured cells. In accordance with this invention, the inhibitor can protect the cleavage of a target protein during cultivation and increase homogeneity of a target molecule, wherein the inhibitor can be a dextran sulfate. This invention also relates to a method of purifying target molecules from the culture medium containing both a target molecule and selected inhibitors by affinity chromatography.

Abstract: It is an object of the present invention to provide an oriented collagen/apatite material wherein an orientation is controlled, and a method of the oriented collagen/apatite material wherein an orientation is controlled. A method of producing an orientated collagen/apatite material according to the present invention, is characterized in that the method comprises; preparing a collagen having an orientation, seeding an osteoblast or a mesenchymal stem cell to produce and fix an apatite having an orientation similar to or almost the same as a direction of an orientation of the collagen on a surface and/or inside of the collagen. Furthermore, in a preferred embodiment of above mentioned method of producing an orientated collagen/apatite material according to the present invention, is characterized in that the osteoblast is an osteoblast like cell or an osteoblast obtained from a living organism.

Abstract: The invention relates to binding molecules against Chikungunya virus, which are able of neutralizing Chikungunya virus infectivity, and which can be used with therapeutic, diagnosis or research purposes, as well as to a pharmaceutical composition comprising said binding molecules.

Abstract: The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and RCS families. Unique antibodies derived from novel immunogens enable said methods and kits.

Abstract: Disclosed are antagonists of PDGF receptor ? (PDGFR?) and VEGF-A, including neutralizing anti-PDGFR? and anti-VEGF-A antibodies, as well as related compositions and methods. Anti-PDGFR? and anti-VEGF-A antibodies disclosed herein include bispecific antibodies capable of binding and neutralizing both PDGFR? and VEGF-A. Also disclosed are methods of treating an neovascular disorder, such as cancer or an neovascular ocular disorder, using a PDGFR? and/or VEGF-A antagonist.

Abstract: Cell culture media are provided herein as are methods of using the media for cell culture and antibody production from cells. Compositions comprising antibodies and fragments thereof, produced by the methods herein are also provided.

Abstract: The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies and therapeutic and diagnostic methods and compositions for using the same.

Abstract: Provided herein is are methods of reducing exacerbations of asthma in an asthma patient, comprising administering to the patient an effective amount of the anti-interleukin-5 receptor (IL-5R) antibody benralizumab or an antigen-binding fragment thereof.

Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.

Abstract: The present disclosure provides compositions and methods relating to antibodies that specifically bind to human erythropoietin. The disclosure provides nucleic acids encoding such antibodies and methods of making and using such antibodies.

Abstract: The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab.

Abstract: Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.

Abstract: The present invention provides anti-KDR monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of a variety of cancers, rheumatoid arthritis, diabetic retinopathy and other diseases associated with aberrant VEGF or KDR expression and/or activity.

Abstract: The present invention provides compositions and methods of use of anti-IGF-1R antibodies or antibody fragments. Preferably the antibodies bind to IGF-1R but not IR; are not agonists for IGF-1R; do not block binding of IGF-1 or IGF-2 to isolated IGF-1R, but effectively neutralize activation of IGF-1R by IGF-1 in intact cells; and block binding of an R1 antibody to IGF-1R. The antibodies may be murine, chimeric, humanized or human R1 antibodies comprising the heavy chain CDR sequences DYYMY (SEQ ID NO:1), YITNYGGSTYYPDTVKG (SEQ ID NO:2) and QSNYDYDGWFAY (SEQ ID NO:3) and the light chain CDR sequences KASQEVGTAVA (SEQ ID NO:4), WASTRHT (SEQ ID NO:5) and QQYSNYPLT (SEQ ID NO:6). Preferably the antibodies bind to an epitope of IGF-1R comprising the first half of the cysteine-rich domain of IGF-1R (residues 151-222). The anti-IGF-1R antibodies may be used for diagnosis or therapy of various diseases such as cancer.

Abstract: The present invention is based on the seminal discovery that targeted immunomodulatory antibodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are able to escape elimination by chemotherapeutic agents or tumor-targeted antibodies via specific immunosuppressive mechanisms in the tumor microenvironment and such ability of cancer cells is recognized as immune tolerance. Such immunosuppressive mechanisms include immunosuppressive cytokines (for example, Transforming growth factor beta (TGF-?)) and regulatory T cells and/or immunosuppressive myeloid dendritic cells (DCs). By conteracting tumor-induced immune tolerance, the present invention provides effective compositions and methods for cancer treatment, optional in combination with another existing cancer treatment.

Abstract: The present invention provides affinity matured humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from mAb 1567 and recognizes the same epitope. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.

Abstract: Provided herein is are methods of increasing forced expiratory volume in one second (FEV1) in an asthma patient, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.

Abstract: Provided herein are methods of improving asthma symptoms, e.g., as measured by an asthma control questionnaire, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.

Abstract: High affinity antibodies were made to gangliosides expressed on tumor cells. The antibodies can be used analytically, diagnostically, therapeutically, and theranostically. The antibodies may be used to target cytotoxic reagents to tumor cells, thus minimizing full-body toxicity. The antibodies may also be used with out added cytotoxin. The antibodies may be detectably labeled or labelable for analytic and diagnostic purposes. The combination of specificity and affinity of the antibodies render them particularly useful.

Abstract: The present invention relates to antibodies that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.

Abstract: Peptide sequences that specifically bind infectious prion protein for the generation of antibodies and therapeutic agents are disclosed herein.

Abstract: The present invention discloses a matrix comprising a modified primary hydroxyl groups containing polysaccharide comprising repeating disaccharide units wherein in at least part of the disaccharide units the primary hydroxyl group is replaced by functional groups selected from halide groups or groups comprising sulfur or phosphorus atoms, like e.g. sulfate groups, sulfonate groups, phosphonate groups and phosphate groups.

Abstract: A method for manufacturing cellulosic material includes: introducing cellulose fibers as cellulosic raw material to a system, conveying the cellulose fibers to an extruder comprising a mixing part and/or a refining part, dosing at least one chemical to the system before the extruder and/or in the extruder and performing a reaction between the cellulose fibers and the chemical(s) at least partly in the extruder, wherein the reaction is performed at a consistency of at least 40%, and/or dosing at least one chemical to the system before the extruder and/or in the extruder and mixing the cellulose fibers and the chemical(s) in the mixing part of the extruder, wherein the mixing step is performed at a consistency of at least 40%, and/or refining the introduced cellulose fibers at least partly in the refining part of the extruder, wherein the refining step is performed at a consistency of at least 5%.

Abstract: The present invention describes an analytical method for detecting and quantitating poly-sulfated oligosaccharides, including Fondaparinux sodium, using hydrophilic interaction ultra-performance liquid chromatography (HILIC-UPLC) coupled with a charged aerosol detector (CAD) or a mass spectrometer (MS). This analytical method provides in-process control in a total synthesis of highly sulfated oligosaccharides by separation, quantification and mass identification. Systems and conditions utilizing such methods are also provided.

Abstract: The present invention pertains to a fluoropolymer [polymer (F)] comprising: recurring units derived from vinylidene fluoride (VDF), and from 0.01% to 5% by moles of recurring units derived from at least one (meth)acrylic monomer [monomer (MA)] having formula (I) here below: wherein: R1, R2 and R3, equal to or different from each other, are independently selected from a hydrogen atom and a C1-C3 hydrocarbon group, and ROH represents a hydrogen atom or a C1-C5 hydrocarbon moiety comprising at least one hydroxyl group, said polymer (F) comprising end groups having formula —CF2H and/or —CF2CH3 in an amount of at least 30 mmoles per Kg of vinylidene fluoride (VDF) recurring units. The invention also pertains to a process for the manufacture of said polymer (F) and to use of said polymer (F) as binders for the manufacture of electrodes or for the manufacture of membranes.

Abstract: Arylclobutene-containing multi-functional monomers are useful in the preparation of arylcyclobutene-based polymer coatings. Compositions comprising one or more arylclobutene-containing multi-functional monomers and one or more oligomers comprising as polymerized units one or more arylcyclobutene monomer provide arylcyclobutene-based polymer coatings having reduced stress. Such compositions are useful in the manufacture of electronic devices.

Abstract: The present invention relates to a slurry process for preparing an ethylene polymer having a melt flow ratio F/P, which is the ratio among the melt index value measured according to ASTM 1238 condition “F” and the melt index value measured according to ASTM 1238 condition “P” of equal to or lower than 27, carried out in two or more stages of polymerization at temperatures in the range from 60 to 120° C., in which at least two of the said two or more polymerization stages are carried out under different amounts of molecular weight regulator, said process being carried out in the presence of (A) a solid catalyst component comprising Ti, Mg, halogen, having a porosity (PF), measured by the mercury method and due to pores with radius equal to, or lower than, 1 ?m, of at least 0.3 cm3/g and a surface area determined by BET method, of lower than 100 m2/g, and being further characterized by the fact that more than 50% of the titanium atoms are in a valence state lower than 4 and (B) of an organoaluminum compound.

Abstract: The present technology relates to a process for polymerizing or copolymerizing ethylenically unsaturated monomers in the presence of free-radical polymerization initiators, wherein the polymerization is carried out in a continuously operated tubular reactor at temperatures from 100° C. to 350° C. and pressures from 180 MPa to 340 MPa, with a specific reactor surface area Asp of 2 m2/(t/h) to 5.5 m2/(t/h), and the tubular reactor has a specific ratio RDsp of 0.0050 MPa?1 to 0.0069 MPa?1 and an inner surface which has a surface roughness Ra of 2 ?m or less.

Abstract: Disclosed are procatalyst compositions having an internal electron donor which includes a substituted amide ester and optionally an electron donor component. Ziegler-Natta catalyst compositions containing the present procatalyst compositions exhibit improved catalyst activity and/or improved catalyst selectivity and produce propylene-based olefins with broad molecular weight distribution.

Abstract: The present application provides, among other things, compounds and methods for metathesis reactions. In some embodiments, a provided compound has the structure of formula I, II or III. In some embodiments, R1 of formula I, II or III comprises an electron-withdrawing group. In some embodiments, the present invention provides methods for preparing provided compounds.

Abstract: Provided herein are ethylene copolymers, methods for making such copolymers, and compositions made from such copolymers. The ethylene copolymers have 70 wt. % to 85 wt. % of units derived from ethylene and at least 12 wt. % of units derived from at least one ?-olefin having 3 to 20 carbon atoms. The copolymers preferably further have a weight-average molecular weight (Mw) ranging from about 50,000 to about 200,000 g/mol, melting point of at least 100° C., ratio of Mw/Mn of about 1.5 to about 3.5, a content of group 4 metals of no more than 25 ppm, and a ratio of wt ppm Group 4 metals/wt ppm Group 5 metals of at least 3. Such copolymers may be particularly useful as viscosity modifiers for lubricating oil compositions.

Abstract: A polymer composition comprising an ethylene alpha-olefin copolymer, wherein the polymer composition is characterized as having (a) a density in the range of from greater than about 0.910 g/cc to about 0.930 g/cc, as determined according to ASTM D1505; (b) a melt index in the range of from greater than about 0.5 g/10 min to about 3 g/10 min, as determined by ASTM D1238, Condition 190° C./2.16 kg; (c) a molecular weight distribution of from about 3.4 to about 12, as determined by gel permeation chromatography (GPC); (d) a weight average molecular weight of from greater than about 85 kg/mol to about 160 kg/mol, as determined by gel permeation chromatography (GPC); and (e) a z-average molecular weight of from greater than about 210 kg/mol to about 500 kg/mol, as determined by gel permeation chromatography (GPC).

Abstract: A multimodal polyethylene polymer having an MFR2 of 0.05 to 10.0 g/10 min, a density of 940 kg/m3 or more, a tensile modulus of 900 MPa or more wherein Formula (I).

Abstract: Catalyst compositions containing activator-supports and half-metallocene titanium phosphinimide complexes or half-metallocene titanium iminoimidazolidide complexes are disclosed. These catalyst compositions can be used to produce olefin polymers having relatively broad molecular weight distributions and low levels of long chain branching.

Abstract: The present invention provides a curable composition, which contains a crosslinking aid (B) containing three or more allyl groups in the molecule in an amount of 1 to 50 parts by mass, polyfunctional (meth)acrylic compound (C) in an amount of 5 to 50 parts by mass, and photopolymerization initiator (D1) and/or thermal polymerization initiator (D2) in an amount of 0.1 to 10 parts by mass, respectively, as a polymerization initiator (D) to 100 parts by mass of allyl group-terminated allyl ester oligomer (A); wherein the crosslinking aid (B) containing allyl group is a compound containing three or more allyl groups in a molecule; wherein the content of impurities derived from the crosslinking aid (B) in the curable composition is less than 0.1 mass %; wherein the content of the (meth)acrylic compound containing a hydroxyl group in a molecule (C1) in the curable composition is 0.5 to 30 mass %.

Abstract: Provided is a curable composition for imprints having good patternability and dry etching resistance. Disclosed is a curable composition for imprints comprising a polymerizable monomer (Ax) having a substituent having an aromatic group and having a molecular weight of 100 or more, and a photopolymerization initiator.

Abstract: An oxygen scavenger composition for food packaging application comprising (I) a polymeric resin, (II) one or more oligomeric photosensitizers, (III) a metal salt, preferably Cu stearate or Mn stearate; (IV) a sacrificial oxidizable substrate, and optionally (V) additional components.

Abstract: Fiber-reinforced polyurethane structures are made with a polyol composition that contains a particulate filler such as calcium carbonate, in addition to the fibers. The polyol composition and the polyisocyanate composition are selected such that the polymer formed in their reaction has a calculated molecular weight between crosslinks (Mc) of from 300 to 420. The polyisocyanate component contains a urethane-modified MDI and/or a urethane-modified polymeric MDI.

Abstract: Embodiments of the invention provide for viscoelastic polyurethane foams. The foams are made from reaction system which includes (a) an isocyanate reactive component, (b) a isocyanate component, (c) one or more blowing agents, (d) a catalyst component, and (e) a silicone based surfactant. The isocyanate reactive component includes at least (i) from 25 to 80% by weight of at least one polyoxyethylene capped polyoxypropylene/polyoxyethylene polyol having a combined number average equivalent weight from 1300 to 1700, a polyoxyethylene percentage of between 75% and 95% by weight of the combined amounts of polyoxypropylene and polyoxyethylene, and a primary OH percentage of between 80 and 95% of the total number of OH groups of the polyoxyethylene capped polyoxypropylene/polyoxyethylene polyol, and (ii) from 5 to 30% by weight of the isocyanate reactive component of at least one low functionality polyol having a functionality of between 1.5 and 2.

Abstract: The present invention provides an epoxy resin having a low melting point, low melt viscosity, excellent solvent solubility, and excellent processability. Also, the present invention provides an epoxy resin composition and a cured product thereof having excellent fluidity, processability, flexibility, adhesion, and thermal conductivity. The epoxy resin is represented by general formula (I) below (Q: an alkylene chain having a C1-C9 linear part which may have a C1-C18 alkyl group in a side chain, or a linkage chain having an ether bond present between two continuous methylene groups in the alkylene chain; A: a phenylene unit in which 2 to 4 phenylene groups are bonded directly or through a linkage chain, or a naphthylene unit, n: 0 to 10). The epoxy resin composition contains the epoxy resin and a curing agent. The composition includes the epoxy resin.

Abstract: Compositions containing a divinylarene dioxide and a hydroxy-substituted dioxide compound and having relatively low viscosity and reduced volatility are used as underfills in the manufacture of electronic assemblies.

Abstract: The present invention relates to a fast curing two component epoxy resin which has excellent adhesion properties to glazed surfaces and a short tack free time at ambient and low temperature conditions. The invention also relates a process for the rehabilitation of glazed surfaces, especially glazed ceramic surfaces or glazed cement surfaces. Furthermore the present invention describes a cartridge for the transportation and risk-free mixing of the described epoxy resin on site.

Abstract: The invention provides complexes in which ligands (e.g., calixarene-related compounds) are coordinated to a metal colloid, e.g. a gold colloid. In exemplary embodiments, two or more ligands complexed to the metal colloid are larger than the metal colloid, thus providing an accessible metal center. The complexes can be immobilized on a substrate. The complexes of the invention are useful as tunable and highly robust isolated metal colloids that find use in binding of molecules and catalysis of chemical reactions.

Abstract: The present invention relates to a drawn PET fiber that can provide a cap ply cord and the like showing more improved modulus and good dimensional stability, a PET tire cord, and a tire including the same. The drawn PET fiber may be a fiber including 90 mol % or more of PET, of which the crystallinity is 53% or more, the amorphous orientation factor (AOF) is 0.15 or less, and the birefringence index is 0.14 to 0.16, after heat-treating the same at 230° C. for 1 minute under the initial load of 20 g/1000 d.

Abstract: The present invention relates to an arc-extinguishing insulation material molded product provided in the vicinity of a contact point between contactors in a gas circuit breaker. The arc-extinguishing insulation material molded product includes a polymer which contains a carbon-oxygen bond in the main chain, and in which a part of or all of terminal atoms are non-hydrogen atoms.

Abstract: A method including combining an aniline monomer, an oxidant, water and an organic solvent; subjecting the combination to acoustic mixing to form an emulsion; and recovering a polyaniliine from the combination. A method including combining a aniline monomer, an oxidant, water and an organic solvent; forming a polyaniline by acoustic mixing the combination; and recovering the polyaniliine from the combination. A method including forming a combination of an aniline monomer, an oxidant, water and an organic solvent in the absence of an emulsifier; acoustic mixing the combination for a time period to form a polyaniline; and recovering a polyaniliine from the combination.